Custom service
Quenchbody Generation Service
A fluorescent antibody that lights up only when it binds.
A Quenchbody is an antibody fragment carrying a fluorophore near the antigen-binding site. In the unbound state, tryptophan residues in the framework quench the dye; when antigen binds, the local environment changes, the dye is displaced from the quenching residues, and fluorescence increases. The result is a reagent that reports binding as light, in real time, without a wash step or a secondary antibody.
The label is introduced in one of two ways. A cysteine is engineered at a permissive site near the CDR and a maleimide-activated dye is coupled to it; or, for a fully recombinant route, an amber codon is placed at the chosen position and the dye is incorporated through orthogonal tRNA/synthetase suppression during expression. The second gives a homogeneous, single-label product and is the reason the format works reproducibly.
Not every antibody yields a responsive sensor. The dye must sit close enough to be quenched and far enough to be released on binding, and the magnitude of the response depends on the local tryptophan landscape. We screen several positions and both heavy and light chain contexts, and report the signal-to-background achieved rather than promising a number. Typical responders show two- to ten-fold increases.
Service Highlights
Where it fits
Quenchbodies suit point-of-care and field assays where a wash step is impractical, and kinetic binding studies where a labelled antigen is unavailable. They are also used for intracellular imaging when the fragment can be delivered, and for continuous monitoring in bioprocess.
They are less suitable for assays needing very high sensitivity, since the signal change is smaller than an enzyme-amplified readout, and for antibodies whose CDR region tolerates no modification at all. In those cases a labelled antigen or a FRET pair is the better design.
Documentation and QC
Each variant is delivered with a fluorescence emission spectrum, a titration curve with antigen, a fold-change value, and a matrix blank. The limit of detection in the intended matrix is reported alongside the response magnitude, because a large fold-change in buffer can still be invisible in serum.
Frequently asked questions
How large a signal can we expect?
Two- to ten-fold for a well-positioned dye in a VHH; smaller for Fab constructs where the dye is farther from the paratope. We report the measured value per variant rather than a target.
Does antigen binding have to be reversible?
For kinetic assays, yes. Quenchbodies respond reversibly, which distinguishes them from covalent or trapping formats and allows dissociation to be followed.
Can this work in whole blood?
Rarely without dilution, because haemoglobin absorbs in the same range as many dyes. Diluted plasma or serum is the practical matrix, and we test it before promising performance.
Send the antibody sequence and the matrix the assay will run in. If the CDR cannot tolerate a label, we will say so after the positional screen rather than after the assay fails.
Service Highlights
- Positional screening. Several labelled variants generated per antibody and ranked by antigen-dependent fluorescence change.
- Homogeneous assay format. No wash, no secondary reagent, and a signal that can be read kinetically.
- Fab, scFv and VHH scaffolds. VHH constructs give the largest responses because the dye sits closer to the paratope.
- Site-specific incorporation. Amber suppression with a fluorescent non-canonical amino acid, giving a single defined label position.
- Reversible response. Binding is reported in real time, so association and dissociation kinetics can be followed on a plate reader.
- Assay transfer. Validated in buffer and in diluted serum or plasma, with the matrix effect quantified.
How the work runs
Antibody and scaffold selection
Sequence and structure are reviewed to identify permissive positions near the CDR. VHH scaffolds are preferred where available.
Mutant design and cloning
Cysteine or amber-codon variants are designed at three to five positions and cloned into an expression vector with a purification tag.
Expression and labelling
Periplasmic expression in E. coli, purification by IMAC, then maleimide coupling or amber suppression with a fluorescent amino acid.
Response screening
Fluorescence measured before and after antigen addition; variants ranked by fold-change and by the concentration range over which the response is linear.
Matrix testing
Response confirmed in buffer, diluted serum and cell culture medium, with background fluorescence from the matrix recorded.
Assay development
The best variant is formatted into a plate or lateral-flow assay, with a standard curve and a limit of detection reported.
Specifications & timeline
- Format
- Fab / scFv / VHH — single fluorophore
- Readout
- Homogeneous — no wash steps
- Timeline
- 6–10 weeks — to validated sensor
- Scaffolds
- Fab, scFv, VHH
- Dyes
- ATTO, Alexa Fluor, TAMRA and Cy3 maleimides; fluorescent non-canonical amino acids for amber suppression
- Response
- Typically 2–10 fold fluorescence increase on antigen binding
- Timeline
- 6–10 weeks from sequence to validated sensor
- Matrix
- Validated in buffer and 10–50% serum or plasma
- Deliverables
- Plasmid, purified Quenchbody, response curves, assay protocol
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.